ANTHONY D. ELIAS
University of Colorado Cancer Center · 484 works · 24,263 citations · h-index 73
Top works
- Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
- Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced Myelosuppression
- GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MAN
- An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
- Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
- A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.
- Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
- Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- Adaptive Randomization of Neratinib in Early Breast Cancer
- Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer
- Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
- Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
- Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
- Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
- NCCN Guidelines Insights: Breast Cancer, Version 1.2017
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- High-dose ifosfamide with mesna uroprotection: a phase I study.
- A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.